Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals subject to Rule 16b-3

RIGL Stock  USD 26.70  0.61  2.34%   
About 55% of Rigel Pharmaceuticals' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Rigel Pharmaceuticals suggests that some traders are interested. Rigel Pharmaceuticals' investing sentiment shows overall attitude of investors towards Rigel Pharmaceuticals.
  
Filed transaction by Rigel Pharmaceuticals Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Rigel insider trading alert for grant of common stock by Raul Rodriguez, CEO President, on 7th of February 2023. This event was filed by Rigel Pharmaceuticals Inc with SEC on 2023-02-07. Statement of changes in beneficial ownership - SEC Form 4. Raul Rodriguez currently serves as ceo and president director and member of fin. committee of Rigel Pharmaceuticals

Cash Flow Correlation

Rigel Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Rigel Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Rigel Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Rigel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Rigel Pharmaceuticals Fundamental Analysis

We analyze Rigel Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rigel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rigel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Target Price

Target Price Comparative Analysis

Rigel Pharmaceuticals is currently under evaluation in target price category among its peers.

Rigel Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rigel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Rigel Pharmaceuticals Related Equities

FBIOFortress Biotech   9.52   
0%
100.0%
LPTXLeap Therapeutics   5.16   
0%
54.0%
CDTXCidara Therapeutics   4.82   
0%
50.0%
ELEVElevation Oncology   3.28   
0%
34.0%
ENVBEnveric Biosciences   3.13   
0%
32.0%
XFORX4 Pharmaceuticals   2.94   
0%
30.0%
TERNTerns Pharmaceuticals   1.55   
0%
16.0%
PIRSPieris Pharmaceuticals   1.37   
0%
14.0%
DAWNDay One   0.89   
0%
9.0%
MREOMereo BioPharma   0.59   
0%
6.0%
INZYInozyme Pharma   0.38   
0%
3.0%
ZURAZura Bio   1.63   
17.0%
0%
RVPHReviva Pharmaceuticals   2.61   
27.0%
0%
IMMXImmix Biopharma   4.07   
42.0%
0%
ABOSAcumen Pharmaceuticals   6.78   
71.0%
0%
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
Check out Rigel Pharmaceuticals Hype Analysis, Rigel Pharmaceuticals Correlation and Rigel Pharmaceuticals Performance.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.48)
Earnings Share
0.27
Revenue Per Share
8.979
Quarterly Revenue Growth
0.966
Return On Assets
0.0461
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.